AngioDynamics, Inc. (ANGO): Price and Financial Metrics

AngioDynamics, Inc. (ANGO)

Today's Latest Price: $10.64 USD

0.55 (5.45%)

Updated Jun 3 3:18pm

Add ANGO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 132 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

ANGO Stock Summary

  • With a year-over-year growth in debt of -89.22%, Angiodynamics Inc's debt growth rate surpasses only 2% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Angiodynamics Inc is reporting a growth rate of 304.96%; that's higher than 95.53% of US stocks.
  • As for revenue growth, note that ANGO's revenue has grown -39.32% over the past 12 months; that beats the revenue growth of just 4.74% of US companies in our set.
  • Stocks that are quantitatively similar to ANGO, based on their financial statements, market capitalization, and price volatility, are DHX, MTRN, VIVO, PLPC, and ROG.
  • ANGO's SEC filings can be seen here. And to visit Angiodynamics Inc's official web site, go to
ANGO Daily Price Range
ANGO 52-Week Price Range

ANGO Stock Price Chart More Charts

ANGO Price/Volume Stats

Current price $10.64 52-week high $22.09
Prev. close $10.09 52-week low $7.48
Day low $10.13 Volume 178,569
Day high $10.75 Avg. volume 305,922
50-day MA $10.23 Dividend yield N/A
200-day MA $13.82 Market Cap 400.34M

AngioDynamics, Inc. (ANGO) Company Bio

AngioDynamics designs, manufactures, and sells various medical, surgical, and diagnostic devices for vascular access, surgery, peripheral vascular disease, and oncology in the United States and internationally. The company was founded in 1988 and is based in Latham, New York.

ANGO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Angiodynamics Inc. To summarize, we found that Angiodynamics Inc ranked in the 0th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 100%. In terms of the factors that were most noteworthy in this DCF analysis for ANGO, they are:

  • The company's compound free cash flow growth rate over the past 5.65 years comes in at -0.74%; that's greater than only 0.58% of US stocks we're applying DCF forecasting to.
  • The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than only 10.81% of the free cash flow producing stocks we're observing.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ANGO, try AGHC, ALC, CSII, ELAN, and HAPP.

ANGO Latest News Stream

Event/TimeNews Detail
Loading, please wait...

ANGO Latest Social Stream

Loading social stream, please wait...

View Full ANGO Social Stream

Latest ANGO News From Around the Web

Below are the latest news stories about Angiodynamics Inc that investors may wish to consider to help them evaluate ANGO as an investment opportunity.

Edited Transcript of ANGO earnings conference call or presentation 7-Apr-20 12:00pm GMT

Q3 2020 AngioDynamics Inc Earnings Call

Yahoo | June 1, 2020

AngioDynamics (ANGO) Down 1.6% Since Last Earnings Report: Can It Rebound?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Investment Research | May 7, 2020

AngioDynamics to Present at the UBS Virtual Global Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the UBS Virtual Global Healthcare Conference at 9:10 a.m. ET on Monday, May 18, 2020. A live webcast

Business Wire | May 7, 2020

AngioDynamics slows spending as hospitals delay elective surgeries amid coronavirus

"We have had great momentum heading into this, and we want to be sure we're ready to continue to build upon that momentum as we exit whenever that may be," said CEO Jim Clemmer.

Yahoo | April 13, 2020

AngioDyanamics (ANGO) Q3 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.

Zacks Investment Research | April 9, 2020

Read More 'ANGO' Stories Here

ANGO Price Returns

1-mo 13.07%
3-mo -5.92%
6-mo -30.95%
1-year -44.44%
3-year -31.18%
5-year -34.56%
YTD -33.54%
2019 -20.47%
2018 21.05%
2017 -1.42%
2016 38.96%
2015 -36.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0521 seconds.